More than 100,000 patients with heart failure in China are using our new AI-enabled platform, AI Nurse, to manage their condition and aim for better health.

Researchers from industry and academia will leverage new chemistry to hit difficult drug targets.

Novartis drug hunters leverage machine learning and automation to power a faster, smarter way to navigate to new drugs.

A Novartis team couriers an experimental treatment across Europe to a patient as transit grinds to a halt.

Bertrand Bodson explains the Novartis strategy for digital innovation in asthma care.

Improved versions of our new digital platform for heart failure disease management in China have been developed since April, 2020 rollout.

Investing in innovative treatments is vital to alleviate the suffering caused by multiple sclerosis (MS).

Doyle describes the road to improving patient outcomes across Europe through the HARMONY Alliance.

Novartis is working to tackle the problem of counterfeit drugs, which are a threat to patient health.

AI is already accelerating drug discovery and health delivery. It has great potential to accelerate research, workflow and processes, and even reengineer entire healthcare systems. But what challenges must be addressed first? Shahram Ebadollahi and Ann Aerts share the ideas they discussed at the Intelligent Health summit in Basel this week.